Enzymotec (ENZY) and Its Competitors Financial Review

Enzymotec (NASDAQ: ENZY) is one of 34 publicly-traded companies in the “Commodity Chemicals” industry, but how does it weigh in compared to its peers? We will compare Enzymotec to similar companies based on the strength of its valuation, risk, analyst recommendations, profitability, dividends, earnings and institutional ownership.

Profitability

This table compares Enzymotec and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Enzymotec -14.52% -3.88% -3.58%
Enzymotec Competitors -29.19% 27.54% 5.29%

Risk and Volatility

Enzymotec has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Comparatively, Enzymotec’s peers have a beta of 1.17, indicating that their average stock price is 17% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Enzymotec and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enzymotec 0 2 0 0 2.00
Enzymotec Competitors 103 768 1147 32 2.54

Enzymotec presently has a consensus target price of $8.00, suggesting a potential downside of 27.93%. As a group, “Commodity Chemicals” companies have a potential downside of 0.72%. Given Enzymotec’s peers stronger consensus rating and higher possible upside, analysts plainly believe Enzymotec has less favorable growth aspects than its peers.

Institutional & Insider Ownership

28.0% of Enzymotec shares are held by institutional investors. Comparatively, 69.0% of shares of all “Commodity Chemicals” companies are held by institutional investors. 8.3% of shares of all “Commodity Chemicals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Enzymotec and its peers top-line revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Enzymotec $47.01 million -$4.56 million -38.28
Enzymotec Competitors $4.15 billion $892.82 million 33.62

Enzymotec’s peers have higher revenue and earnings than Enzymotec. Enzymotec is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Enzymotec peers beat Enzymotec on 10 of the 12 factors compared.

Enzymotec Company Profile

Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings. Its product suite addresses the entire human life-cycle, from infancy to old age, and comprises ingredients in products ranging from infant formula to nutritional supplements, as well as branded medical foods, sold only under a doctor’s supervision. It markets its product portfolio to established global consumer companies and physicians and target large and growing consumer health and wellness markets. The Company’s clinically-validated products include bio-functional lipid-based compounds designed to address dietary needs, medical disorders and common diseases.

Receive News & Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related companies with our FREE daily email newsletter.

 


Latest News

Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Red Sox Waste Little Time in Firing John Farrell
Red Sox Waste Little Time in Firing John Farrell
Washington Nationals Sans Strasburg for Game 4 at Wrigley
Washington Nationals Sans Strasburg for Game 4 at Wrigley
Red Sox Beat Houston Sunday to Avoid Elimination
Red Sox Beat Houston Sunday to Avoid Elimination


Leave a Reply

 
© 2006-2017 BBNS.